- Immune cells use hunger hormones to help heal skin infections and wounds
- New mRNA cancer vaccine designed to target lymph nodes for stronger immune response
- HIV infection may shorten a person’s life expectancy by about 5 years
- Moderna CEO: The COVID-19 vaccine will be updated every year like the iPhone 1 dose per year
- UK approved the world’s first vaccine for COVID-19 Omicron
- New DNA Repair Approach Successfully Repairs Pathogenic Gene Mutations in Patients’ Kidney Cells
CanSino Adenovirus Vector COVID-19 Vaccine Approved by China with conditions
CanSino Adenovirus Vector COVID-19 Vaccine Approved by China with conditions. The results of the interim analysis of the Phase III clinical trial of Ad5-nCoV showed that: 28 days after a single injection of the vaccine, the overall protective efficacy of the vaccine against all symptoms is 65.28%.
Heavy! Academician Chen Wei’s team and CanSino Biotech’s COVID-19 vaccine conditional listing application accepted.
At noon on February 24, Cansino Biotech Co., Ltd. (hereinafter referred to as “Cansino Bio”) issued an announcement stating that on February 21, the company formally submitted a recombinant new coronavirus vaccine (type 5 adenovirus vector) to China State Food and Drug Administration. The conditional listing application was accepted and accepted.
The recombinant new coronavirus vaccine (type 5 adenovirus vector) is jointly developed by the team of Academician Chen Wei from the Institute of Bioengineering of the Institute of Military Medical Research of the Kansino Academy of Biological Sciences and the trade name is “Kewisha”. At present, the vaccine has carried out global multi-center phase III clinical studies in five countries including Pakistan, Mexico, Russia, Chile and Argentina. More than 40,000 subjects have been vaccinated and interim data analysis has been completed.
The results of the analysis of the data during the phase III clinical trial of the vaccine showed that 28 days after a single injection of the vaccine, the overall protective efficacy of the vaccine against all symptoms was 65.28%; 14 days after the single injection of the vaccine, the overall protective efficacy of the vaccine against all symptoms was 68.83%. The protective effects of the vaccine on severe illnesses were: 90.07% after 28 days of single-shot vaccination; 95.47% after 14 days of single-shot vaccination.
CanSino Biotech stated in the announcement that the results of the vaccine protection efficacy data meet the relevant technical standards of the World Health Organization and the relevant standards in the “Guidelines for Clinical Evaluation of New Coronavirus Preventive Vaccines (Trial)” issued by the National Medical Products Administration.
(source:internet, reference only)